Literature DB >> 12706335

Purification and preliminary characterization of brain aspartoacylase.

Roger A Moore1, Johanne Le Coq, Christopher R Faehnle, Ronald E Viola.   

Abstract

Aspartoacylase catalyzes the deacetylation of N-acetylaspartic acid (NAA) in the brain to produce acetate and L-aspartate. An aspartoacylase deficiency, with concomitant accumulation of NAA, is responsible for Canavan disease, a lethal autosomal recessive disorder. To examine the mechanism of this enzyme the genes encoding murine and human aspartoacylase were cloned and expressed in Escherichia coli. A significant portion of the enzyme is expressed as soluble protein, with the remainder found as inclusion bodies. A convenient enzyme-coupled continuous spectrophotometric assay has been developed for measuring aspartoacylase activity. Kinetic parameters were determined with the human enzyme for NAA and for selected N-acyl analogs that demonstrate relaxed substrate specificity with regard to the nature of the acyl group. The clinically relevant E285A mutant reveals an altered enzyme with poor stability and barely detectable activity, while a more conservative E285D substitution leads to only fivefold lower activity than native aspartoacylase.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12706335     DOI: 10.1016/s0003-9861(03)00055-9

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  13 in total

1.  The impact of structural biology on neurobiology.

Authors:  Ronald E Viola
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-03       Impact factor: 11.205

2.  Modification of aspartoacylase for potential use in enzyme replacement therapy for the treatment of Canavan disease.

Authors:  Stephen Zano; Radhika Malik; Sylvia Szucs; Reuben Matalon; Ronald E Viola
Journal:  Mol Genet Metab       Date:  2010-10-30       Impact factor: 4.797

Review 3.  N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology.

Authors:  John R Moffett; Brian Ross; Peethambaran Arun; Chikkathur N Madhavarao; Aryan M A Namboodiri
Journal:  Prog Neurobiol       Date:  2007-01-05       Impact factor: 11.685

4.  Relationship between enzyme properties and disease progression in Canavan disease.

Authors:  Stephen Zano; Yasanandana S Wijayasinghe; Radhika Malik; Joshua Smith; Ronald E Viola
Journal:  J Inherit Metab Dis       Date:  2012-08-01       Impact factor: 4.982

5.  Enhanced brain distribution of modified aspartoacylase.

Authors:  Nitesh K Poddar; Stephen Zano; Reka Natarajan; Bryan Yamamoto; Ronald E Viola
Journal:  Mol Genet Metab       Date:  2014-07-12       Impact factor: 4.797

6.  Structure of aspartoacylase, the brain enzyme impaired in Canavan disease.

Authors:  Eduard Bitto; Craig A Bingman; Gary E Wesenberg; Jason G McCoy; George N Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-28       Impact factor: 11.205

7.  Comparative computational assessment of the pathogenicity of mutations in the Aspartoacylase enzyme.

Authors:  C George Priya Doss; Hatem Zayed
Journal:  Metab Brain Dis       Date:  2017-09-06       Impact factor: 3.584

8.  Examination of the mechanism of human brain aspartoacylase through the binding of an intermediate analogue.

Authors:  Johanne Le Coq; Alexander Pavlovsky; Radhika Malik; Ruslan Sanishvili; Chengfu Xu; Ronald E Viola
Journal:  Biochemistry       Date:  2008-02-23       Impact factor: 3.162

9.  Mutational analysis of aspartoacylase: implications for Canavan disease.

Authors:  Jeremy R Hershfield; Nagarajan Pattabiraman; Chikkathur N Madhavarao; M A Aryan Namboodiri
Journal:  Brain Res       Date:  2007-03-03       Impact factor: 3.252

10.  Structural modeling of p.V31F variant in the aspartoacylase gene.

Authors:  Navaneethakrishnan Krishnamoorthy; Hatem Zayed
Journal:  Metab Brain Dis       Date:  2016-01-21       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.